Artificial Intelligence is rapidly reshaping the pharmaceutical landscape, from discovery and development to manufacturing and post-approval safety monitoring. As AI becomes more deeply embedded in regulatory decision-making and in processes that directly impact patients, the need for robust governance becomes critical.
Our new report explores how AI governance can be effectively integrated across the medicines lifecycle, ensuring trust, transparency, and regulatory alignment through ongoing dialogue between industry and regulators.
Discover more: https://lnkd.in/eTTRfyYR